prikaz prve stranice dokumenta Targeting PVR (CD155) and its receptors in anti-tumor therapy
  Preuzmi
PDF 1.43 MB
Znanstveni rad - Pregledni rad
Targeting PVR (CD155) and its receptors in anti-tumor therapy
Cellular and Molecular Immunology, 16 (2018), 1; 40-52. https://doi.org/10.1038/s41423-018-0168-y
Kučan Brlić, Paola; Lenac Roviš, Tihana; Cinamon, Guy; Tsukerman, Pini; Mandelboim, Ofer; Jonjić, Stipan

Citirajte ovaj rad

Kučan Brlić, P., Lenac Roviš, T., Cinamon, G., Tsukerman, P., Mandelboim, O. i Jonjić, S. (2018). Targeting PVR (CD155) and its receptors in anti-tumor therapy. Cellular and Molecular Immunology, 16. (1), 40-52. doi: 10.1038/s41423-018-0168-y

Kučan Brlić, Paola, et al. "Targeting PVR (CD155) and its receptors in anti-tumor therapy." Cellular and Molecular Immunology, vol. 16, br. 1, 2018, str. 40-52. https://doi.org/10.1038/s41423-018-0168-y

Kučan Brlić, Paola, Tihana Lenac Roviš, Guy Cinamon, Pini Tsukerman, Ofer Mandelboim i Stipan Jonjić. "Targeting PVR (CD155) and its receptors in anti-tumor therapy." Cellular and Molecular Immunology 16, br. 1 (2018): 40-52. https://doi.org/10.1038/s41423-018-0168-y

Kučan Brlić, P., et al. (2018) 'Targeting PVR (CD155) and its receptors in anti-tumor therapy', Cellular and Molecular Immunology, 16(1), str. 40-52. doi: 10.1038/s41423-018-0168-y

Kučan Brlić P, Lenac Roviš T, Cinamon G, Tsukerman P, Mandelboim O, Jonjić S. Targeting PVR (CD155) and its receptors in anti-tumor therapy. Cellular and Molecular Immunology [Internet]. 01.10.2018. [pristupljeno 26.04.2024.];16(1):40-52. doi: 10.1038/s41423-018-0168-y

P. Kučan Brlić, T. Lenac Roviš, G. Cinamon, P. Tsukerman, O. Mandelboim i S. Jonjić, "Targeting PVR (CD155) and its receptors in anti-tumor therapy", Cellular and Molecular Immunology, vol. 16, br. 1, str. 40-52, Listopad 2018. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:504690. [Citirano: 26.04.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:504690
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Targeting PVR (CD155) and its receptors in anti-tumor therapy
AutorPaola Kučan Brlić
AutorTihana Lenac Roviš
AutorGuy Cinamon
AutorPini Tsukerman
AutorOfer Mandelboim
AutorStipan Jonjić
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Centar za proteomiku)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Sažetak (engleski)
Poliovirus receptor (PVR, CD155) has recently been gaining scientific interest as a therapeutic target in the field of tumor immunology due to its prominent endogenous and immune functions. In contrast to healthy tissues, PVR is expressed at high levels in several human malignancies and seems to have protumorigenic and therapeutically attractive properties that are currently being investigated in the field of recombinant oncolytic virotherapy. More intriguingly, PVR participates in a considerable number of immunoregulatory functions through its interactions with activating and inhibitory immune cell receptors. These functions are often modified in the tumor microenvironment, contributing to tumor immunosuppression. Indeed, increasing evidence supports the rationale for developing strategies targeting these interactions, either in terms of checkpoint therapy (i.e., targeting inhibitory receptors) or in adoptive cell therapy, which targets PVR as a tumor marker.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Pregledni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaCellular and Molecular Immunology
Brojčani podacivol. 16, br. 1, str. 40-52
p-ISSN1672-7681
e-ISSN2042-0226
DOIhttps://doi.org/10.1038/s41423-018-0168-y
URN:NBNurn:nbn:hr:184:504690
Datum objave elektroničkog izdanja2018-10-01
URL dokumentahttp://www.nature.com/articles/s41423-018-0168-y
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno-Dijeli pod istim uvjetima 4.0 međunarodna (CC BY-NC-SA 4.0)
Datum i vrijeme pohrane2018-10-11 08:36:12